Date:			
Your Name:	Yuewei Hao		
Manuscript 7	Fitle:_OGDH is involved in sepsis induced acute lung injury through the MAPK pathway		
Manuscript i	lanuscript number (if known):		
related to th parties whos to transpare	st of transparency, we ask you to disclose all relationships/activities/interests listed below that are e content of your manuscript. "Related" means any relation with for-profit or not-for-profit third se interests may be affected by the content of the manuscript. Disclosure represents a commitment ncy and does not necessarily indicate a bias. If you are in doubt about whether to list a a cativity/interest, it is preferable that you do so.		
The followin	g questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>		

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	<b>X</b> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	<b>X</b> None	
U	testimony	_ <b>X</b> None	
	,		
7	Support for attending	_ <b>X</b> None	
	meetings and/or travel		
8	Patents planned, issued or	<b>X</b> None	
	pending		
9	Participation on a Data	_ <b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <b>X</b> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
	Stock of Stock operans	XNone	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<b>X</b> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fo	allowing hox.
	The authors have no confl	icts of interest to declare	<i>.</i>
DI.		. fallai.a. atatam ant ta :	adianta un un anno mante.

re:
ır Name: Zheng Wang
nuscript Title:_OGDH is involved in sepsis induced acute lung injury through the MAPK pathway
nuscript number (if known):
he interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are ated to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third
ties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	<b>X</b> None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	<b>X</b> None		
U	testimony	_ <b>X</b> None		
	,			
7	Support for attending	_ <b>X</b> None		
	meetings and/or travel			
8	Patents planned, issued or	<b>X</b> None		
	pending			
9	Participation on a Data	_ <b>X</b> None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	<b>X</b> None		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	<b>X</b> None		
	·			
12	Receipt of equipment,	_ <b>X</b> None		
	materials, drugs, medical			
	writing, gifts or other			
10	services			
13	Other financial or non- financial interests	<b>X</b> None		
	illialiciai liiterests			
Ple	ease summarize the above o	onflict of interest in the f	ollowing box:	
_				
	The authors have no confl	icts of interest to declare	2.	
DI-		. falla		

Yo Ma	Date: Your Name: Xinfang Wang Manuscript Title:_OGDH is involved in sepsis induced acute lung injury through the MAPK pathway Manuscript number (if known):			
rel par to	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.			
	e following questions apply nuscript only.	to the author's relationship	os/activities/interests as they relate to the <u>current</u>	
to	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.			
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.			
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	

Time frame: past 36 months

All support for the present

manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)

No time limit for this item.

Grants or contracts from

in item #1 above).

Royalties or licenses

Consulting fees

any entity (if not indicated

2

3

4

 $\mathbf{X}_{\perp}$ 

\_None

**X** None

None

\_None

X

X

5	Payment or honoraria for	<b>X</b> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	<b>X</b> None	
U	testimony	_ <b>X</b> None	
	,		
7	Support for attending	_ <b>X</b> None	
	meetings and/or travel		
8	Patents planned, issued or	<b>X</b> None	
	pending		
9	Participation on a Data	_ <b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <b>X</b> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
	Stock of Stock options	XNone	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<b>X</b> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fo	allowing hox.
	The authors have no confl	icts of interest to declare	<i>.</i>
DI.		. fallai.a. atatam ant ta :	adianta un un anno mante.

Date:\_\_\_

Your Name:\_\_\_ Wenming Zhan\_\_

	anuscript Title:_OGDH is it anuscript number (if known)		ed acute lung injury through the MAPK pathway
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to me	the epidemiology of hypertoedication, even if that medic	ension, you should declare cation is not mentioned in t	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other items
	e time frame for disclosure i	•	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	_ <b>X</b> None	

5	Payment or honoraria for	<b>X</b> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	<b>X</b> None	
U	testimony	_ XNone	
	,		
7	Support for attending	_ <b>X</b> None	
	meetings and/or travel		
8	Patents planned, issued or	<b>X</b> None	
	pending		
9	Participation on a Data	_ <b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <b>X</b> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
	Stock of Stock options	XNone	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<b>X</b> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fo	allowing hox.
	The authors have no confl	icts of interest to declare	<i>.</i>
DI.		. fallai.a. atatam ant ta :	adianta un un anno mante.

Date:
Your Name: Dianshui Wu
Manuscript Title:_OGDH is involved in sepsis induced acute lung injury through the MAPK pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> None	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	_ <b>X</b> None	

5	Payment or honoraria for	<b>X</b> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	<b>X</b> None	
U	testimony	_ XNone	
	,		
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or	<b>X</b> None	
	pending		
9	Participation on a Data	_ <b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <b>X</b> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
	Stock of Stock options	XNone	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<b>X</b> None	
	financial interests		
Please summarize the above conflict of interest in the following box:			
	The authors have no conflicts of interest to declare.		
DI.		. fallai.a. atatam ant ta :	adianta un un anno mante.